A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Trial Number
NCT02866370 (ClinicalTrials.gov Identifier)Contact Person
Status
Closed to Recruitment
Disease Site
Recurrent Ovarian/Rare
Lead Cooperative Group
Participating Groups
GINECO
EORTC-GCG
NSGO-CTU